Experimental Ebola vaccines elicit year-long immune response

Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that last for at least one year. The findings are based on a study of 1,500 adults that began during the West Africa Ebola outbreak.

This post was syndicated from Top Health News -- ScienceDaily. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply